



Contact: Tricia J. Richardson
Senior Manager, Investor Relations
Novavax, Inc.
1 240-268-2031

NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference

Rockville, MD (March 11, 2010) - /PRNewswire-FirstCall/- Novavax, Inc. (NASDAQ:NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer of Novavax will be presenting at the 22nd Annual ROTH OC Growth Stock Conference. The presentation will take place on March 15, 2010 at 8:30 am pacific time at the Ritz Carlton, Laguna Niguel, California. Dr. Singhvi will provide an overview of the company's business strategy, research and development progress and upcoming milestones. A link to the live presentation can be accessed via the company website at www.novavax.com under the Investors tab. An archive of the presentation will be available one hour after the event on the Novavax website for 90 days.

About Novavax, Inc.

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

###